Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.

Sivakami A Pai50 enrolled

Overview

Prospective study to evaluate the efficacy and safety of intravitreal bevacizumab In retinopathy of prematurity (ROP). Bevacizumab 0.75 mg in 0.03 ml was given to stage 2+ or stage 3+ ROP in Zone I or Zone II.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Stage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II.

Interventions

Intravitreal BevacizumabPROCEDURE

Eligibility

Sex: ALLMin age: 32 WeeksMax age: 42 Weeks

Medical Language ↔ Plain English

Inclusion Criteria: stage 2+ or stage 3+ Retinopathy of prematurity in Zone I or Zone II. Informed written consent by parents or guardian. \- Exclusion Criteria: Refusal to give consent Critically ill neonates. \-

Locations (1)

Dubai Hospital

Dubai, UAE, United Arab Emirates

RECRUITING

Outcomes

Primary Outcomes

Regression Of ROP

Time frame: Minimum 6 months follow up after intravitreal Avastin

Secondary Outcomes

Recurrence of ROP

Time frame: minimum 6 months of follow up.

Central Contacts

Sivakami A Pai, MS, DNB, Phd

CONTACT

00971504148256

M A Dekhain, FRCS, MRCOpth

CONTACT

0097142195000 maDekhain@dha.gov.ae

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.